Evidence map›Paper›PMID 34826786›Full record

ArticleEpidemics2021

A quantitative assessment of epidemiological parameters required to investigate COVID-19 burden.

Agnese Zardini, Margherita Galli, Marcello Tirani, Danilo Cereda, Mattia Manica, Filippo Trentini, Giorgio Guzzetta, Valentina Marziano, Raffaella Piccarreta, Alessia Melegaro and 3 more

Open access · goldAbstract read
In one paragraph

Article in Epidemics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. A Markovian model for the spread of the SARS-CoV-2 virus.Automatica : the journal of IFAC, the International Federation of Automatic Control · 2023
    Article
  4. Article
  5. Article
  6. Observational
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Agnese ZardiniBruno Kessler Foundation, Trento, Italy.
Margherita GalliBruno Kessler Foundation, Trento, Italy; Department of Mathematics, Computer Science and Physics, University of Udine, Udine, Italy.
Marcello TiraniDirectorate General for Health, Lombardy Region, Milan, Italy; Health Protection Agency of the Metropolitan Area of Milan, Milano, Italy.
Danilo CeredaDirectorate General for Health, Lombardy Region, Milan, Italy.
Mattia ManicaBruno Kessler Foundation, Trento, Italy.
Filippo TrentiniBruno Kessler Foundation, Trento, Italy; Dondena Centre for Research on Social Dynamics and Public Policy, and CovidCrisisLab, Bocconi University, Milan, Italy.
Giorgio GuzzettaBruno Kessler Foundation, Trento, Italy.
Valentina MarzianoBruno Kessler Foundation, Trento, Italy.
Raffaella PiccarretaDondena Centre for Research on Social Dynamics and Public Policy, and CovidCrisisLab, Bocconi University, Milan, Italy; Department of Decision Sciences, Bocconi University, Milan, Italy.
Alessia MelegaroDondena Centre for Research on Social Dynamics and Public Policy, and CovidCrisisLab, Bocconi University, Milan, Italy; Department of Social and Political Sciences, Bocconi University, Milan, Italy.
Marco AjelliLaboratory for Computational Epidemiology and Public Health, Indiana University School of Public Health, Bloomington, United States.
Piero PolettiBruno Kessler Foundation, Trento, Italy. Electronic address: poletti@fbk.eu.
Stefano MerlerBruno Kessler Foundation, Trento, Italy.
Fondazione Bruno Kessler · ITBocconi University · ITIndiana University Bloomington · USMinistero della Salute · ITRegione Lombardia

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Solid estimates describing the clinical course of SARS-CoV-2 infections are still lacking due to under-ascertainment of asymptomatic and mild-disease cases. In this work, we quantify age-specific probabilities of transitions between stages defining the natural history of SARS-CoV-2 infection from 1965 SARS-CoV-2 positive individuals identified in Italy between March and April 2020 among contacts of confirmed cases. Infected contacts of cases were confirmed via RT-PCR tests as part of contact tracing activities or retrospectively via IgG serological tests and followed-up for symptoms and clinical outcomes. In addition, we provide estimates of time intervals between key events defining the clinical progression of cases as obtained from a larger sample, consisting of 95,371 infections ascertained between February and July 2020. We found that being older than 60 years of age was associated with a 39.9% (95%CI: 36.2-43.6%) likelihood of developing respiratory symptoms or fever ≥ 37.5 °C after SARS-CoV-2 infection; the 22.3% (95%CI: 19.3-25.6%) of the infections in this age group required hospital care and the 1% (95%CI: 0.4-2.1%) were admitted to an intensive care unit (ICU). The corresponding proportions in individuals younger than 60 years were estimated at 27.9% (95%CI: 25.4-30.4%), 8.8% (95%CI: 7.3-10.5%) and 0.4% (95%CI: 0.1-0.9%), respectively. The infection fatality ratio (IFR) ranged from 0.2% (95%CI: 0.0-0.6%) in individuals younger than 60 years to 12.3% (95%CI: 6.9-19.7%) for those aged 80 years or more; the case fatality ratio (CFR) in these two age classes was 0.6% (95%CI: 0.1-2%) and 19.2% (95%CI: 10.9-30.1%), respectively. The median length of stay in hospital was 10 (IQR: 3-21) days; the length of stay in ICU was 11 (IQR: 6-19) days. The obtained estimates provide insights into the epidemiology of COVID-19 and could be instrumental to refine mathematical modeling work supporting public health decisions.

Indexed as

COVID-19Contact TracingHumansPublic HealthRetrospective StudiesSARS-CoV-2Contact tracing dataDisease burdenEpidemiological parametersRisk outcomesSARS-CoV-2

Identifiers

PMID34826786
PMCPMC8595250
OpenAlexW3214456528

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.